Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Literature DB >> 24442143

The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Anna Lasorella¹, Robert Benezra², Antonio Iavarone³.

Abstract

Inhibitor of DNA binding (ID) proteins are transcriptional regulators that control the timing of cell fate determination and differentiation in stem and progenitor cells during normal development and adult life. ID genes are frequently deregulated in many types of human neoplasms, and they endow cancer cells with biological features that are hijacked from normal stem cells. The ability of ID proteins to function as central 'hubs' for the coordination of multiple cancer hallmarks has established these transcriptional regulators as therapeutic targets and biomarkers in specific types of human tumours.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24442143 DOI： 10.1038/nrc3638

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

233 in total

1. Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.

Authors: Anna Lasorella; Judith Stegmüller; Daniele Guardavaccaro; Guangchao Liu; Maria S Carro; Gerson Rothschild; Luis de la Torre-Ubieta; Michele Pagano; Azad Bonni; Antonio Iavarone
Journal: Nature Date: 2006-06-28 Impact factor: 49.962

2. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

Authors: Hao Geng; Brooks L Rademacher; Janet Pittsenbarger; Chung-Ying Huang; Christopher T Harvey; Marie C Lafortune; Anne Myrthue; Mark Garzotto; Peter S Nelson; Tomasz M Beer; David Z Qian
Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701

Review 3. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

Authors: Thomas Brabletz; Andreas Jung; Simone Spaderna; Falk Hlubek; Thomas Kirchner
Journal: Nat Rev Cancer Date: 2005-09 Impact factor: 60.716

4. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.

Authors: V Riechmann; I van Crüchten; F Sablitzky
Journal: Nucleic Acids Res Date: 1994-03-11 Impact factor: 16.971

5. Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.

Authors: Alessia Ciarrocchi; Simonetta Piana; Roberto Valcavi; Giorgio Gardini; Bruno Casali
Journal: Eur J Cancer Date: 2010-12-09 Impact factor: 9.162

6. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Authors: Mariano Ponz-Sarvisé; Paul A Nguewa; María J Pajares; Jackeline Agorreta; María D Lozano; Miriam Redrado; Ruben Pio; Carmen Behrens; Ignacio I Wistuba; Carlos E García-Franco; Jesús García-Foncillas; Luis M Montuenga; Alfonso Calvo; Ignacio Gil-Bazo
Journal: Clin Cancer Res Date: 2011-05-03 Impact factor: 12.531

7. Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma.

Authors: Kong-Jia Luo; Jing Wen; Xuan Xie; Jian-Hua Fu; Rong-Zhen Luo; Qiu-Liang Wu; Yi Hu
Journal: Ann Thorac Surg Date: 2012-04-04 Impact factor: 4.330

8. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling.

Authors: Hye-Min Jeon; Xun Jin; Joong-Seob Lee; Se-Yeong Oh; Young-Woo Sohn; Hyo-Jung Park; Kyeung Min Joo; Woong-Yang Park; Do-Hyun Nam; Ronald A DePinho; Lynda Chin; Hyunggee Kim
Journal: Genes Dev Date: 2008-08-01 Impact factor: 11.361

9. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors: Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal: Nature Date: 2012-08-12 Impact factor: 49.962

10. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Authors: Winnie F Tam; Ting-Lei Gu; Jing Chen; Benjamin H Lee; Lars Bullinger; Stefan Fröhling; Andrew Wang; Stefano Monti; Todd R Golub; D Gary Gilliland
Journal: Blood Date: 2008-06-17 Impact factor: 22.113

163 in total

1. Id2 Mediates Differentiation of Labyrinthine Placental Progenitor Cell Line, SM10.

Authors: Kaisa Selesniemi; Renee E Albers; Thomas L Brown
Journal: Stem Cells Dev Date: 2016-06-17 Impact factor: 3.272

2. TLR4 Deficiency Impairs Oligodendrocyte Formation in the Injured Spinal Cord.

Authors: Jamie S Church; Kristina A Kigerl; Jessica K Lerch; Phillip G Popovich; Dana M McTigue
Journal: J Neurosci Date: 2016-06-08 Impact factor: 6.167

Review 3. Pancreatic cancer stem cells.

Authors: Ya-Yun Zhu; Zhou Yuan
Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166

The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

1. Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.

2. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

Review 3. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

4. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.

5. Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.

6. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

7. Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma.

8. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling.

9. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

10. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

1. Id2 Mediates Differentiation of Labyrinthine Placental Progenitor Cell Line, SM10.

2. TLR4 Deficiency Impairs Oligodendrocyte Formation in the Injured Spinal Cord.

Review 3. Pancreatic cancer stem cells.

4. Snail interacts with Id2 in the regulation of TNF-α-induced cancer cell invasion and migration in OSCC.

5. USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.

6. Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.

7. Id2 controls specification of Lgr5⁺ intestinal stem cell progenitors during gut development.

8. BMP signaling and its pSMAD1/5 target genes differentially regulate hair follicle stem cell lineages.

9. Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.

Review 10. New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.